Core First Bank & Trust Gilead Sciences, Inc. Transaction History
Core First Bank & Trust
- $167 Million
- Q4 2024
A detailed history of Core First Bank & Trust transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Core First Bank & Trust holds 900 shares of GILD stock, worth $86,526. This represents 0.05% of its overall portfolio holdings.
Number of Shares
900
Previous 1,230
26.83%
Holding current value
$86,526
Previous $103,000
19.42%
% of portfolio
0.05%
Previous 0.06%
Shares
8 transactions
Others Institutions Holding GILD
# of Institutions
1,993Shares Held
993MCall Options Held
10.1MPut Options Held
8.85M-
Black Rock Inc. New York, NY121MShares$11.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$11.1 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.36 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.94 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.78 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $120B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...